Gain Therapeutics Reports Positive Phase 1b Results for GT-02287 in Parkinson’s Disease
Gain Therapeutics Reports Positive Phase 1b Results for GT-02287 in Parkinson’s Disease at AD/PD 2026
March 18, 2026 – Bethesda, MD: Gain Therapeutics, Inc. (Nasdaq: GANX), a clinical-stage biotechnology company specializing in allosteric small molecule therapies, delivered a series of significant clinical and preclinical updates at the prestigious AD/PD™ 2026 International Conference on Alzheimer’s and Parkinson’s Disease in Copenhagen, Denmark.
Key Highlights from the Report
- New Clinical Data: Gain presented additional biomarker and clinical data from its ongoing Phase 1b clinical study of its lead candidate, GT-02287, in Parkinson’s disease (PD), including both idiopathic and GBA1 mutation-associated PD.
- Reduction in Disease Biomarkers: The company reported a reduction in cerebrospinal fluid (CSF) levels of glucosylsphingosine (GluSph), a pathogenic biomarker related to GCase dysfunction, after 90 days of GT-02287 treatment in participants with elevated baseline GluSph.
- Emerging Biomarker Data: In participants with high baseline CSF GluSph, DOPA decarboxylase (DDC) levels—a newly identified PD biomarker—were also reduced after 90 days of dosing, suggesting an effect on dopaminergic neuron function.
- Durable Clinical Improvement: Motor symptoms, as measured by the sum of MDS-UPDRS Part II and III scores, remained stable after 150 days of dosing. Importantly, those with high baseline GluSph in CSF saw greater improvement, with a 6.7-point difference versus those with low baseline GluSph.
- Strong Patient Retention & Tolerability: Of 19 participants who completed Part 1, 16 elected to continue in the ongoing nine-month extension, reflecting positive tolerability and patient confidence. To date, 14 have completed five months of extension dosing, and a Data Monitoring Committee cleared the study to continue without changes.
- Novel Preclinical Pipeline: Gain also unveiled “first-in-class” preclinical data for a new chemical series of allosteric GCase modulators, led by GT-04686, which are now ready for IND-enabling studies targeting PD and other neurological disorders.
- Platform Validation: The company’s proprietary Magellan™ drug discovery platform continues to generate structurally distinct and promising CNS-penetrant compounds for PD and potentially other neurodegenerative or rare diseases.
- Regulatory and Funding Support: The GT-02287 program has received backing from The Michael J. Fox Foundation, The Silverstein Foundation, and multiple European innovation grants, underscoring third-party validation and financial support.
Details Investors Need to Know
-
Potentially Price-Sensitive Information:
- The newly released clinical and biomarker data further demonstrate disease-modifying potential for GT-02287, not just symptomatic relief. This is a significant differentiator in PD treatment and, if confirmed in larger studies, could position the asset as a first-in-class disease-modifying therapy.
- Durable efficacy signals after 150 days and ongoing safety data support advancement to later-stage trials. The observed biomarker changes (GluSph and DDC reductions) are also highly relevant, as they point to the drug’s direct action on disease biology.
- The readiness of GT-04686 and related compounds for IND-enabling studies signals pipeline expansion and long-term value creation beyond GT-02287.
- Investor risk is mitigated by continued financial support from reputable foundations and public agencies, as well as confirmation that the study is continuing without safety-related modifications.
-
Upcoming Milestones:
- The nine-month extension of the Phase 1b trial is expected to complete in September 2026, with further data presentations planned throughout the year.
- IND-enabling studies for GT-04686 are anticipated, possibly adding another clinical candidate to the pipeline in the near future.
-
Competitive Differentiation:
- Unlike most PD therapies focused on symptomatic control, GT-02287 and the new chemical series are designed to restore enzyme function and address the underlying disease mechanism, which could reshape the PD treatment landscape if successful.
Overview of GT-02287 and Pipeline
GT-02287 is a novel, orally administered, brain-penetrant allosteric modulator of glucocerebrosidase (GCase), developed for PD patients with or without GBA1 mutations. Preclinical data show restoration of GCase function, reduction of relevant pathologies (e.g., alpha-synuclein aggregation, mitochondrial and lysosomal dysfunction), and improved motor and behavioral outcomes. Phase 1 studies in healthy volunteers established safety and CNS exposure; in Phase 1b PD patients, GT-02287 demonstrated biomarker engagement and potential clinical benefit.
The company’s pipeline includes additional undisclosed preclinical assets for lysosomal storage disorders, metabolic diseases, and oncology, all discovered using the Magellan™ platform.
Management Commentary
Gene Mack, President and CEO, emphasized the significance of the evolving biomarker and clinical evidence, stating that GT-02287 appears to target the causative biology of PD. He highlighted that improvements in MDS-UPDRS scores were correlated with reductions in GluSph and DDC, supporting the drug’s disease-modifying potential. Mack noted the company’s aspiration to shift the treatment paradigm from symptomatic relief to disease modification.
Dr. Jonas Hannestad, Chief Medical Officer, confirmed that the Phase 1b extension study is ongoing and expects completion in September 2026, with additional data to be presented later in the year.
Access to Conference Materials
Investors and analysts can access the conference poster on Gain’s website in the Science and Technology section: https://gaintherapeutics.com/science-and-technology/posters
Contact Information
Disclaimer
This article contains forward-looking statements based on current expectations and assumptions regarding future events. Actual results may differ materially. Investors should consider all risks described in Gain Therapeutics’ filings with the SEC and not place undue reliance on forward-looking statements. This article does not constitute investment advice.
View Gain Therapeutics, Inc. Historical chart here
